# Douglas Reed

> Douglas Reed is a Series B investor at Hatteras Venture Partners backing Health Care. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Hatteras Venture Partners](https://shizune.co/investors/profile/hatteras-venture-partners)
- Location: Durham, United States
- Total investments: 7
- Lead investor: 43%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/douglas-reed-36407b24
- Facebook: https://www.facebook.com/doug.reed.1654

Douglas Reed is a General Partner at Hatteras Venture Partners and was a Managing Director at Vector Fund Management. He attended The Wharton School and the University of Missouri-Kansas City School of Medicine.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 57% |
| Biotechnology | 4 | 57% |
| Pharmaceutical | 4 | 57% |
| Medical Device | 3 | 43% |
| Medical | 1 | 14% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 43% |
| Series C | 2 | 29% |
| Series A | 1 | 14% |
| Series D | 1 | 14% |
| Funding Round | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Contego Medical | Contego Medical has developed a family of novel embolic protection devices. Its portfolio of integrated, multi-functional products is designed to improve patient outcomes and procedural efficiency during revascularization treatment for carotid artery disease, peripheral artery disease, and deep vein thrombosis. The company has FDA clearance for thePaladin Carotid PTA Balloon System with Integrated Embolic Protection, the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection, and the Excipio SV Thrombectomy Device. |  | Series B | Apr 17, 2015 |  |
| Coferon | Coferon is a biotechnology company that employs bioorthogonal linker chemistry to deliver therapeutic molecules in component parts that self assembles inside target cells. The Company is based at the Long Island High Tech Incubator on the campus of Stony Brook University in Stony Brook, New York. | $12M | Series B | Jul 16, 2012 |  |
| TetraLogic Pharmaceuticals | TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. ItsNecrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology. | $23M | Series C | Jan 04, 2011 |  |
| TetraLogic Pharmaceuticals | TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. ItsNecrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology. | $32M | Series C | Aug 10, 2010 |  |
| SpineAlign Medical | SpineAlign Medical, Inc. designs and manufactures medical devices for spinal surgery. The company is based in San Jose, California. |  |  | Jun 03, 2008 |  |
| Viamet Pharmaceuticals | Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allowsthem to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors. |  | Series A | Jun 07, 2007 |  |
| CGI Pharmaceuticals | Founded out of Yale University, CGI (formerly Cellular Genomics Inc.) began operations in 2000. CGI, in conjunction with several biotech and pharmaceutical partners (Pfizer, Serono, Lilly, Affymetrix, and Schering AG), utilized a unique chemical-genetics approach known as “ASKA” (Analog Sensitive Kinase Alleles) to understand kinase function.CGI Pharmaceuticals is dedicated to the discovery and development of breakthrough small molecule therapeutics for a broad range of oncology and allergy/autoimmune/inflammatory disease (AAID) indications. The Company’s fully integrated drug discovery infrastructure comprises proprietary kinase biology and chemistry, extensive lead generation and optimization capabilities, as well as drug metabolism/pharmacokinetics (DMPK) expertise.Utilizing its comprehensive chemistry capabilities, CGI has generated a proprietary small molecule kinase inhibitor library of over 50,000 compounds (all compounds designed and synthesized by CGI). To date, CGI has been awarded 8 U.S. patents covering its novel collection of kinase inhibitors. Moreover, all three of CGI’s drug discovery and development programs are based on hits obtained from CGI’s library. |  | Series C | Jan 21, 2004 |  |

7 of 7 investments shown.

## Co-investors
- [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 2 deals together
- [HealthCare Ventures](https://shizune.co/investors/profile/healthcare-ventures) — VC Fund, 2 deals together
- [The Vertical Group](https://shizune.co/investors/profile/the-vertical-group) — VC Fund, 2 deals together
- [Ascent Biomedical Ventures](https://shizune.co/investors/profile/ascent-biomedical-ventures) — VC Fund, 1 deal together
- [Intersouth Partners](https://shizune.co/investors/profile/intersouth-partners) — VC Fund, 1 deal together
- [Lilly Ventures](https://shizune.co/investors/profile/lilly-ventures) — VC Fund, 1 deal together

## About Hatteras Venture Partners

VC Fund · Durham, United States

Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.

5 contacts available at Hatteras Venture Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Douglas Reed | General Partner | https://shizune.co/investors/profile/douglas-reed |
| Jeff Terrell | General Partner | https://shizune.co/investors/profile/jeff-terrell |
| Myla Lai-Goldman | Venture Partner | https://shizune.co/investors/profile/myla-lai-goldman |
| Christy L. Shaffer | General Partner | https://shizune.co/investors/profile/christy-l-shaffer |
| Clay B. Thorp | General Partner and Co-Founder | https://shizune.co/investors/profile/clay-b-thorp |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Douglas Reed invest in?

Douglas Reed invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Series C stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co